<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331666</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR1041</org_study_id>
    <nct_id>NCT03331666</nct_id>
  </id_info>
  <brief_title>Impact of LDL-cholesterol Lowering on Platelet Activation</brief_title>
  <official_title>Impact of LDL-cholesterol Lowering on Platelet Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal is to assess the impact of Evolocumab therapy on platelet function of&#xD;
      familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab&#xD;
      is a humanized monoclonal antibody that targets circulating PCSK9, increases hepatic LDL&#xD;
      receptor, decreases plasma LDL cholesterol and reduces risk of cardiovascular events.&#xD;
      Evolocumab (brand name Rapatha) has been approved by FDA along with diet and maximally&#xD;
      tolerated statin therapy in adults with FH or atherosclerotic heart or blood vessel problems,&#xD;
      who need additional lowering of LDL cholesterol.&#xD;
&#xD;
      The secondary goal is to determine if platelet activation or the response to Evolocumab&#xD;
      therapy is modified by rs3184504 polymorphism. The investigators believe that these&#xD;
      investigations will complement ongoing studies to demonstrate that Evolocumab reduces&#xD;
      athero-thrombotic risk and aid the decision-making as to whether Evolocumab can reduce the&#xD;
      atherothrombotic risk in acute coronary syndrome (ACS) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlipidemia as exemplified by familial hypercholesterolemia is associated with increased&#xD;
      platelet activation and an underlying pro-coagulant state. Hyperlipidemia primes platelets&#xD;
      and increases platelet activation in response to various agonists. Plasma cholesterol levels&#xD;
      appear to have a critical role in modulating platelet activity as hypercholesterolemia&#xD;
      increases platelet activation more potently than hypertriglyceridemia. Increased platelet&#xD;
      reactivity may contribute to the increased risk of atherothrombosis associated with&#xD;
      hypercholesterolemia. Plasma levels of platelet activation markers such as&#xD;
      thrombin-antithrombin complex (TAT), soluble P-selectin (sP-selectin), soluble CD40L (sCD40L)&#xD;
      or P-selectin exposure at surface of platelets are increased in hypercholesterolemic&#xD;
      patients. Increased levels of the platelet activation markers are associated with increased&#xD;
      platelet membrane cholesterol content in hypercholesterolemia.Statins may show antithrombotic&#xD;
      properties.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated Prematurely due to COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">February 4, 2020</completion_date>
  <primary_completion_date type="Actual">February 4, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (P2Y12 Reaction Units (PRU))</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 84</time_frame>
    <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (Aspirin Reaction Unit (ARU))</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 84</time_frame>
    <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>REPATHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a clinical diagnosis of familial hypercholesterolemia (FH)&#xD;
&#xD;
          -  Subjects who are referred to Dr. Ginsberg's Lipid Practice for treatment with PCSK9&#xD;
             inhibitor&#xD;
&#xD;
          -  Subjects with LDL cholesterol levels &gt;100 mg/dl on baseline treatment with statins&#xD;
             and/or ezetimibe&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children under 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Ginsberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nan Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med. 1974 Feb 21;290(8):434-8.</citation>
    <PMID>4359434</PMID>
  </reference>
  <reference>
    <citation>CONNOR WE, HOAK JC, WARNER ED. Massive thrombosis produced by fatty acid infusion. J Clin Invest. 1963 Jun;42:860-6.</citation>
    <PMID>14022629</PMID>
  </reference>
  <reference>
    <citation>Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.</citation>
    <PMID>22214850</PMID>
  </reference>
  <reference>
    <citation>Harmon JT, Tandon NN, Hoeg JM, Jamieson GA. Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. Blood. 1986 Aug;68(2):498-505. Review.</citation>
    <PMID>3524709</PMID>
  </reference>
  <reference>
    <citation>Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 1993 Oct;44(2):112-6.</citation>
    <PMID>8266915</PMID>
  </reference>
  <reference>
    <citation>Dav√¨ G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998 Mar 17;97(10):953-7.</citation>
    <PMID>9529262</PMID>
  </reference>
  <reference>
    <citation>Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001 Nov 13;104(20):2395-400.</citation>
    <PMID>11705814</PMID>
  </reference>
  <reference>
    <citation>Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 2002 Dec;32(12):901-8.</citation>
    <PMID>12534449</PMID>
  </reference>
  <reference>
    <citation>Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013 Jan 15;127(2):251-7. doi: 10.1161/CIRCULATIONAHA.112.145334. Review.</citation>
    <PMID>23319813</PMID>
  </reference>
  <reference>
    <citation>Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.</citation>
    <PMID>16226162</PMID>
  </reference>
  <reference>
    <citation>Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Dav√¨ G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002 Jul 23;106(4):399-402.</citation>
    <PMID>12135935</PMID>
  </reference>
  <reference>
    <citation>Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. Epub 2006 Aug 14.</citation>
    <PMID>16907931</PMID>
  </reference>
  <reference>
    <citation>Pawelczyk M, Chmielewski H, Kaczorowska B, Przyby≈Ça M, Baj Z. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci. 2015 Mar 16;11(1):115-21. doi: 10.5114/aoms.2015.49216. Epub 2015 Mar 14.</citation>
    <PMID>25861297</PMID>
  </reference>
  <reference>
    <citation>Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation. 2012 Jul 3;126(1):92-103. doi: 10.1161/CIRCULATIONAHA.112.095554. Epub 2012 May 21.</citation>
    <PMID>22615342</PMID>
  </reference>
  <reference>
    <citation>Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.</citation>
    <PMID>24678979</PMID>
  </reference>
  <reference>
    <citation>Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.</citation>
    <PMID>25773607</PMID>
  </reference>
  <reference>
    <citation>Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1. Review.</citation>
    <PMID>27046161</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv. 2013 Feb;6(2):169-79. doi: 10.1016/j.jcin.2012.09.013.</citation>
    <PMID>23428009</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. J Thromb Thrombolysis. 2014 May;37(4):427-34. doi: 10.1007/s11239-013-0966-0.</citation>
    <PMID>23852152</PMID>
  </reference>
  <reference>
    <citation>Sikora J, Kostka B, Marczyk I, Krajewska U, Cha≈Çubi≈Ñski M, Broncel M. Effect of statins on platelet function in patients with hyperlipidemia. Arch Med Sci. 2013 Aug 30;9(4):622-8. doi: 10.5114/aoms.2013.36905. Epub 2013 Aug 8.</citation>
    <PMID>24049520</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Nan Wang</investigator_full_name>
    <investigator_title>Associate Professor of Medical Sciences (in Medicine) at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia, Hypercholesterolemia, atherothrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03331666/Prot_SAP_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Evolocumab</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Due to Covid-19 pandemic, the trial was prematurely terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who have a clinical diagnosis of familial hypercholesterolemia and are referred for treatment with PCSK9 inhibitor, with LDL cholesterol levels ‚â•70 mg/dl on baseline treatment with statins and/or ezetimibe or intolerant to statin and/or ezetimibe.</population>
      <group_list>
        <group group_id="B1">
          <title>Evolocumab</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (P2Y12 Reaction Units (PRU))</title>
        <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU</description>
        <time_frame>Day 7, Day 14, Day 21, Day 28, Day 84</time_frame>
        <population>Adult male and female subjects who have a clinical diagnosis of familial hypercholesterolemia and referred for treatment with PCSK9 inhibitor, with LDL cholesterol levels ‚â•70 mg/dl on baseline treatment with statins and/or ezetimibe or intolerant to statin and/or ezetimibe. Of the four participants reported in this study, one participant per arm had ADP assessed by PRU Test (evolocumab and placebo arms) and one participant per arm had ADP assessed by Aspirin assay (evolocumab and placebo arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Evolocumab</title>
            <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (P2Y12 Reaction Units (PRU))</title>
          <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU</description>
          <population>Adult male and female subjects who have a clinical diagnosis of familial hypercholesterolemia and referred for treatment with PCSK9 inhibitor, with LDL cholesterol levels ‚â•70 mg/dl on baseline treatment with statins and/or ezetimibe or intolerant to statin and/or ezetimibe. Of the four participants reported in this study, one participant per arm had ADP assessed by PRU Test (evolocumab and placebo arms) and one participant per arm had ADP assessed by Aspirin assay (evolocumab and placebo arms).</population>
          <units>PRU</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P2Y12 Test, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P2Y12 Test, Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P2Y12 test, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P2Y12 Test, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P2Y12 Test, Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (Aspirin Reaction Unit (ARU))</title>
        <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU)</description>
        <time_frame>Day 7, Day 14, Day 21, Day 28, Day 84</time_frame>
        <population>Adult male and female subjects who have a clinical diagnosis of familial hypercholesterolemia and referred for treatment with PCSK9 inhibitor, with LDL cholesterol levels ‚â•70 mg/dl on baseline treatment with statins and/or ezetimibe or intolerant to statin and/or ezetimibe. Of the four participants reported in this study, one participant per arm had ADP assessed by PRU Test (evolocumab and placebo arms) and one participant per arm had ADP assessed by Aspirin assay (evolocumab and placebo arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Evolocumab</title>
            <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (Aspirin Reaction Unit (ARU))</title>
          <description>ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU)</description>
          <population>Adult male and female subjects who have a clinical diagnosis of familial hypercholesterolemia and referred for treatment with PCSK9 inhibitor, with LDL cholesterol levels ‚â•70 mg/dl on baseline treatment with statins and/or ezetimibe or intolerant to statin and/or ezetimibe. Of the four participants reported in this study, one participant per arm had ADP assessed by PRU Test (evolocumab and placebo arms) and one participant per arm had ADP assessed by Aspirin assay (evolocumab and placebo arms).</population>
          <units>ARU</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aspirin Test, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521"/>
                    <measurement group_id="O2" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspirin Test Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608"/>
                    <measurement group_id="O2" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspirin Test, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                    <measurement group_id="O2" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspirin Test, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530"/>
                    <measurement group_id="O2" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspirin Test, Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406"/>
                    <measurement group_id="O2" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Evolocumab</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.&#xD;
Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nan Wang</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>212-342-1761</phone>
      <email>nw30@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

